I have extensive experience in performing Indirect Treatment Comparisons (ITCs), a versatile tool that provides estimates of comparative effectiveness in the absence of head-to-head trials.
Moreover, I have expertise in performing survival analyses and longitudinal analyses of data from Phase II and Phase III clinical trials. These provide valuable insights to support HEOR and Market Access activities.
Health economic models are fundamental tools required by a large number of HTA agencies to support decision-making and inform reimbursement recommendations.
I have experience in developing such models, ranging from cost-minimization and budget impact analyses to more sophisticated cost-effectiveness models.
A Global Value Dossier (GVD) is a detailed document that consolidates key evidence about a pharmaceutical product.
I have experience writing value stories and GVDs that support market access activities. Thanks to a solid understanding of the market access dynamics, I know how to effectively communicate the value of a new product to payers and decision-makers.
My ultimate goal is to create tools that provide a strong basis for the P&R negotiations and lead to a positive reimbursement recommendation in the target countries.
I both have a strong understanding of HEOR processes and knowledge of the market access dynamics.
I have long-standing collaborations with multiple consultants in Europe and Canada. This garantees access to a broad range of expertise.